| 2.995 -0.035 (-1.16%) | 09-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.96  |
1-year : | 4.3 |
| Resists | First : | 3.39 |
Second : | 3.69 |
| Pivot price | 3.32 |
|||
| Supports | First : | 2.92 |
Second : | 2.42 |
| MAs | MA(5) : | 3.15 |
MA(20) : | 3.36 |
| MA(100) : | 3.62 |
MA(250) : | 2.89  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.3 |
D(3) : | 15.2 |
| RSI | RSI(14): 32.6 |
|||
| 52-week | High : | 5.05 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ NRXP ] has closed below the lower bollinger band by 6.2%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ NRXP ] is to continue within current trading range. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.09 - 3.12 | 3.12 - 3.14 |
| Low: | 2.87 - 2.9 | 2.9 - 2.91 |
| Close: | 2.96 - 3 | 3 - 3.03 |
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Sat, 26 Sep 2026
NRx Pharmaceuticals, Inc. (NRXP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Fri, 25 Sep 2026
NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans - simplywall.st
Thu, 24 Sep 2026
NRx Pharmaceuticals, Inc. (NRXP) stock price, news, quote and history - Yahoo Finance UK
Mon, 21 Sep 2026
Why NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Is In Focus Now? - Kalkine Media
Fri, 11 Sep 2026
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE - GlobeNewswire
Fri, 14 Aug 2026
NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 43 (M) |
| Shares Float | 36 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 27.1 (%) |
| Shares Short | 8,670 (K) |
| Shares Short P.Month | 6,200 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0 |
| Profit Margin | 0 % |
| Operating Margin | -590.5 % |
| Return on Assets (ttm) | -64 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.03 |
| Sales Per Share | 0.07 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -5.88 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 38.25 |
| Price to Cash Flow | -6.56 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|